SynthesisThe Lancet. Oncology2021
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG)PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
189 papers cite itlatest 60 shown
this paperpooled ittrialcites it